Oncology JP Morgan 2023 – Adi Hoess pharmaphorum editor-in-chief Jonah Comstock joins Adi Hoess, CEO of Affimed, at the Zeppelin Hotel in San Francisco, to learn about
News AACR: Affimed builds case for natural killer cell therapy Affimed says new data from a phase 1/2 trial of its natural killer (NK) cell engager therapy AFM13 provide further evidence of its efficacy in treating CD30+ Hodgkin and non-Hodgkin lymphom
News Affimed and Roche ink $5bn plus cancer immunotherapy deal Deal is based on natural killer cell therapeutics
News GSK adds EU to Blenrep checklist as FDA sets new PDUFA date GSK has added the EMA to the list of regulatory bodies approving Blenrep for multiple myeloma, but whether the FDA is next is still an open question.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
